−865.50 MHKD
5.99 BHKD
209.46 M
About SHENZHEN HEPALINK PHARMACEUTICAL
Sector
CEO
Yu Shan
Headquarters
Shenzhen
Website
Employees (FY)
2.08 K
Founded
1998
ISIN
CNE100003YN2
FIGI
BBG00VNYVMK6
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the research, production and distribution of heparin sodium bulk drugs. It offers heparin sodium products including Food and Drug Administration (FDA) grade heparin sodium ingredients and ordinary grade heparin sodium ingredients. The company was founded by Li Tan, Li Li and Shan Yu on April 21, 1998 and is headquartered in Shenzhen, China.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 9989 is 3.04 HKD — it has increased by 2.01% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange SHENZHEN HEPALINK PHARMACEUTICAL stocks are traded under the ticker 9989.
SHENZHEN HEPALINK PHARMACEUTICAL is going to release the next earnings report on Apr 30, 2024. Keep track of upcoming events with our Earnings Calendar.
9989 stock is 2.00% volatile and has beta coefficient of 0.70. Check out the list of the most volatile stocks — is SHENZHEN HEPALINK PHARMACEUTICAL there?
9989 earnings for the last quarter are 0.04 HKD per share, whereas the estimation was 0.16 HKD resulting in a −73.12% surprise. The estimated earnings for the next quarter are 0.04 HKD per share. See more details about SHENZHEN HEPALINK PHARMACEUTICAL earnings.
SHENZHEN HEPALINK PHARMACEUTICAL revenue for the last quarter amounts to 1.51 B HKD despite the estimated figure of 2.29 B HKD. In the next quarter revenue is expected to reach 1.60 B HKD.
Yes, you can track SHENZHEN HEPALINK PHARMACEUTICAL financials in yearly and quarterly reports right on TradingView.
9989 stock has risen by 6.67% compared to the previous week, the month change is a 8.19% rise, over the last year SHENZHEN HEPALINK PHARMACEUTICAL has showed a 40.97% decrease.
9989 net income for the last quarter is −1.00 B HKD, while the quarter before that showed 63.44 M HKD of net income which accounts for −1.68 K% change. Track more SHENZHEN HEPALINK PHARMACEUTICAL financial stats to get the full picture.
Today SHENZHEN HEPALINK PHARMACEUTICAL has the market capitalization of 4.28 B, it has increased by 4.80% over the last week.
Yes, 9989 dividends are paid annually. The last dividend per share was 0.11 HKD. As of today, Dividend Yield (TTM)% is 3.84%. Tracking SHENZHEN HEPALINK PHARMACEUTICAL dividends might help you take more informed decisions.
Like other stocks, 9989 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SHENZHEN HEPALINK PHARMACEUTICAL stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 25, 2024, the company has 2.08 K employees. See our rating of the largest employees — is SHENZHEN HEPALINK PHARMACEUTICAL on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SHENZHEN HEPALINK PHARMACEUTICAL technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SHENZHEN HEPALINK PHARMACEUTICAL stock shows the neutral signal. See more of SHENZHEN HEPALINK PHARMACEUTICAL technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on SHENZHEN HEPALINK PHARMACEUTICAL future price: according to them, 9989 price has a max estimate of 6.92 HKD and a min estimate of 3.90 HKD. Read a more detailed SHENZHEN HEPALINK PHARMACEUTICAL forecast: see what analysts think of SHENZHEN HEPALINK PHARMACEUTICAL and suggest that you do with its stocks.